リソソーム酸性リパーゼ欠損症治療の市場規模、シェア、動向分析レポート：適応症別、治療法別、地域別、セグメント予測、2025年～2030年

リソソーム酸性リパーゼ欠損症治療市場の成長と動向：

Grand View Researchの最新レポートによると、世界のリソソーム酸性リパーゼ欠損症治療の市場規模は、2030年までに4億3,320万米ドルに達し、2025年から2030年までのCAGRは7.2％を記録すると予測されています。

アンメットニーズの高さ、有病率の上昇、酵素補充療法の普及が、市場を牽引する主な要因のいくつかです。

LAL欠損症（LAL-D）は、LAL遺伝子の変異により、患者がコレステリルエステルやトリグリセリドを分解できない希少なタイプのリソソーム貯蔵障害です。その結果、肝臓、脾臓、血管壁に脂質が蓄積します。LAL欠損症は進行性の疾患であり、多臓器にわたる臨床症状、重大な医学的合併症、特に乳幼児の肝不全による早期死亡を伴います。

2015年まで、世界のLAL欠損症治療市場は、承認された治療法がなかったため、緩やかな成長でした。医療は支持療法に限られ、手術やスタチンなどの脂質改善薬が治療の主役であり続けました。2015年、Alexion Pharmaのカヌマ（セベリパーゼ・アルファ）が承認され、LAL-D領域に酵素補充療法（ERT）が参入しました。カヌマはリソソームのコレステロールエステルおよびトリアシルグリセロールを特異的に加水分解する酵素で、LAL欠損症の患者に静脈内投与されます。現在、カヌマは主要市場においてウォルマン病（WD）とコレステリルエステル貯蔵症（CESD）の両方で承認されている唯一の薬剤です。

治療に基づくと、支持療法が2017年の市場において主要な収益貢献者でした。しかし、ERT分野は、カヌマの継続的な取り込みに支えられ、予測期間中に最も速い成長を記録すると予想されます。患者の大半が診断されていないか誤診されているため、疾患の予後は依然として不良です。そのため、疾患の生物学を理解し、耐性を克服して毒性を最小限に抑えることを目的とした効果的な治療法を開発するための広範な研究が依然として強く求められています。

リソソーム酸性リパーゼ欠損症治療市場のレポートハイライト

• CESDは人生の後半に発現し、白人およびヒスパニック系住民に多く、約30万人に1人が罹患しています。
• ドイツは欧州市場の最前線に位置し、高い有病率とERTクラスの薬剤が利用可能であることが市場を牽引しています。
• ERTクラスにおけるカヌマの承認は、LAL-D欠損症の治療法に対する根本的な転換を強調します。
• 未開拓のLAL-D患者集団における唯一の長期治療薬としてのカヌマの先行優位性により、ERT分野は予測期間中に最も急成長すると予測されます。
• スタチン系薬剤は、同クラスのジェネリック医薬品との競合激化とアレクシオンのカヌマの採用拡大により市場シェアが低下すると予想されます。
• LAL欠損症の対象患者数の増加と限られた治療介入は、この市場で新規治療法の開発に投資する企業にとって大きな商機となります。
• 予後不良による疾患診断の認識不足と薬剤入手の遅れが市場の成長を抑制する可能性があります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 リソソーム酸性リパーゼ欠損症治療市場の変数、動向、範囲

• 市場系統の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 業界分析 - ポーターのファイブフォース分析
  • PESTLE分析

第4章 リソソーム酸性リパーゼ欠損症治療市場：適応症ビジネス分析

• 適応症市場シェア、2024年・2030年
• 適応症セグメントダッシュボード
• 市場規模・予測と動向分析、適応症別、2018～2030年
• ウォルマン病（WD）
• コレステロールエステル蓄積症（CESD）

第5章 リソソーム酸性リパーゼ欠損症治療市場：治療ビジネス分析

• 治療市場シェア、2024年と2030年
• 治療セグメントダッシュボード
• 市場規模・予測と動向分析、治療別、2018年～2030年
• 酵素補充療法（ERT）
• 支持療法
• 脂質改質剤
• その他

第6章 リソソーム酸性リパーゼ欠損症治療市場：地域推定・動向分析

• 地域別市場シェア分析、2024年・2030年
• 地域市場ダッシュボード
• 市場規模、予測動向分析、2018年～2030年：
• 北米
  • 国別、2018年～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 国別、2018年～2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • デンマーク
  • スウェーデン
• アジア太平洋
  • 国別、2018年～2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • 国別、2018年～2030年
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 国別、2018年～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 参加企業概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル / 一覧
  • Alexion Pharmaceuticals, Inc.（AstraZeneca）
  • Amgen Inc.
  • BioCrick BioTech
  • Lupin
  • Merck KGaA
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global lysosomal acid lipase deficiency treatment market, by region, 2018 - 2030 (USD Million)
• Table 4 Global lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 5 Global lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 6 North America lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
• Table 7 North America lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 8 North America lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 9 U.S lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 10 U.S Lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 11 Canada lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 12 Canada lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 13 Mexico lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 14 Mexico lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 15 Europe lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
• Table 16 Europe lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 17 Europe lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 18 UK lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 19 UK Lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 20 Germany lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 21 Germany lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 22 France lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 23 France Lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 24 Italy lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 25 Italy lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 26 Spain lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 27 Spain lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 28 Norway lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 29 Norway Lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 30 Denmark lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 31 Denmark lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 32 Sweden lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 33 Sweden lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 34 Asia Pacific lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
• Table 35 Asia Pacific lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 36 Asia Pacific lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 37 Japan lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 38 Japan lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 39 China lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 40 China lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 41 India lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 42 India lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 43 Australia lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 44 Australia lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 45 South Korea lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 46 South Korea lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 47 Thailand lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 48 Thailand lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 49 Latin America lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
• Table 50 Latin America lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 51 Latin America lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 52 Brazil lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 53 Brazil lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 54 Argentina lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 55 Argentina lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 56 Middle East & Africa Lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
• Table 57 Middle East & Africa lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 58 Middle East & Africa lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 59 South Africa lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 60 South Africa lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 61 Saudi Arabia lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 62 Saudi Arabia lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 63 UAE lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 64 UAE lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 65 Kuwait lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
• Table 66 Kuwait lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Lysosomal acid lipase deficiency treatment market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Indication and treatment outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 Lysosomal acid lipase deficiency treatment market dynamics
• Fig. 12 Lysosomal acid lipase deficiency treatment market: Porter's five forces analysis
• Fig. 13 Lysosomal acid lipase deficiency treatment market: PESTLE analysis
• Fig. 14 Lysosomal acid lipase deficiency treatment market: Indication segment dashboard
• Fig. 15 Lysosomal acid lipase deficiency treatment market: Indication market share analysis, 2024 & 2030
• Fig. 16 Wolman disease (WD) market, 2018 - 2030 (USD Million)
• Fig. 17 Cholesteryl ester storage disease (CESD) market, 2018 - 2030 (USD Million)
• Fig. 18 Lysosomal acid lipase deficiency treatment market: Treatment segment dashboard
• Fig. 19 Lysosomal acid lipase deficiency treatment market: Treatment market share analysis, 2024 & 2030
• Fig. 20 Enzyme replacement therapy (ERT) market, 2018 - 2030 (USD Million)
• Fig. 21 Supportive care market, 2018 - 2030 (USD Million)
• Fig. 22 Lipid modifying agents market, 2018 - 2030 (USD Million)
• Fig. 23 Others market, 2018 - 2030 (USD Million)
• Fig. 24 Lysosomal acid lipase deficiency treatment market revenue, by region
• Fig. 25 Regional marketplace: Key takeaways
• Fig. 26 Regional marketplace: Key takeaways
• Fig. 27 North America lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 28 U.S. country dynamics
• Fig. 29 U.S. lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 30 Canada country dynamics
• Fig. 31 Canada lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 32 Mexico country dynamics
• Fig. 33 Mexico lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 34 Europe lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 35 UK country dynamics
• Fig. 36 UK lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 37 Germany country dynamics
• Fig. 38 Germany lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 39 France country dynamics
• Fig. 40 France lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 41 Italy country dynamics
• Fig. 42 Italy lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 43 Spain country dynamics
• Fig. 44 Spain lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 45 Norway country dynamics
• Fig. 46 Norway lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 47 Sweden country dynamics
• Fig. 48 Sweden lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 49 Denmark country dynamics
• Fig. 50 Denmark lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 51 Asia Pacific lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 52 Japan country dynamics
• Fig. 53 Japan lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 54 China country dynamics
• Fig. 55 China lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 56 India country dynamics
• Fig. 57 India lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 58 Australia country dynamics
• Fig. 59 Australia lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 60 South Korea country dynamics
• Fig. 61 South Korea lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 62 Thailand country dynamics
• Fig. 63 Thailand lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 64 Latin America lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 65 Brazil country dynamics
• Fig. 66 Brazil lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 67 Argentina country dynamics
• Fig. 68 Argentina lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 69 MEA lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 70 South Africa country dynamics
• Fig. 71 South Africa lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 72 Saudi Arabia country dynamics
• Fig. 73 Saudi Arabia lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 74 UAE country dynamics
• Fig. 75 UAE lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 76 Kuwait country dynamics
• Fig. 77 Kuwait lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
• Fig. 78 Company categorization
• Fig. 79 Company market position analysis
• Fig. 80 Strategic framework

Lysosomal Acid Lipase Deficiency Treatment Market Growth & Trends:

The global lysosomal acid lipase deficiency treatment market size is expected to reach USD 433.2 million by 2030, registering a CAGR of 7.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. High unmet needs, rising prevalence, and increasing uptake of enzyme replacement therapy are some of the primary factors driving the market.

LAL deficiency (LAL-D) is a rare type of lysosomal storage disorder in which patients are unable to breakdown cholesteryl esters and triglycerides due to a mutation in the LAL gene. As a result, there is an accumulation of lipids in the liver, spleen, and walls of blood vessels. LAL deficiency is a progressive disease with multi-systemic clinical manifestations, significant medical complications, and early mortality due to liver failure, especially among infants.

Until 2015, the global LAL deficiency treatment market witnessed modest growth due to a lack of approved treatments for the disease. Medical care was limited to supportive care, with surgery and lipid-modifying drugs such as statins remained the mainstay for treatment. In 2015, approval of Alexion Pharma's Kanuma (sebelipase alfa) marked the entry of enzyme replacement therapy (ERT) in the LAL-D space. Kanuma is a hydrolytic lysosomal cholesterol ester and triacylglycerol specific enzyme, administered intravenously in patients with LAL deficiency. Currently, Kanuma is the only drug approved for both Wolman disease (WD) and Cholesteryl Ester Storage Disease (CESD) in the key markets.

Based on treatment, supportive care was the leading revenue contributor in the market in 2017. However, the ERT segment is expected to register the fastest growth during the forecast period, supported by continued uptake of Kanuma. Disease prognosis remains poor, as a majority of patients are either undiagnosed or misdiagnosed. Thus, there remains a strong need for extensive research to understand disease biology and develop effective therapeutic options with the goal to overcome resistance and minimize toxicity.

Lysosomal Acid Lipase Deficiency Treatment Market Report Highlights:

• CESD manifests later in life and is more prevalent among Caucasians and Hispanic populations, affecting approximately 1 in 300,000 individuals.
• Germany is at the forefront of the Europe market and is driven by high disease prevalence and availability of drugs in the ERT class.
• Approval of Kanuma in ERT class highlight a fundamental shift in treatment approach to LAL-D deficiency.
• The ERT segment is estimated to be the fastest-growing during the forecast period, owing to Kanuma's first-mover advantage as the only long-term treatment in untapped LAL-D patient population pool.
• Statins are anticipated to lose market share due to rising competition from generics within the class and increasing uptake of Alexion's Kanuma.
• Rising eligible patient population and limited therapeutic intervention for LAL deficiency offer a strong commercial opportunity for players to invest in developing novel treatments in this market.
• Lack of awareness in disease diagnosis and delayed access to medications due to poor prognosis may restrain the growth of the market.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Treatment
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Lysosomal Acid Lipase Deficiency Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Lysosomal Acid Lipase Deficiency Treatment Market: Indication Business Analysis

• 4.1. Indication Market Share, 2024 & 2030
• 4.2. Indication Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 4.4. Wolman Disease (WD)
  • 4.4.1. Wolman Disease (WD) Market, 2018 - 2030 (USD Million)
• 4.5. Cholesteryl Ester Storage Disease (CESD)
  • 4.5.1. Cholesteryl Ester Storage Disease (CESD) Market, 2018 - 2030 (USD Million)

Chapter 5. Lysosomal Acid Lipase Deficiency Treatment Market: Treatment Business Analysis

• 5.1. Treatment Market Share, 2024 & 2030
• 5.2. Treatment Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
• 5.4. Enzyme Replacement Therapy (ERT)
  • 5.4.1. Enzyme Replacement Therapy (ERT) Market, 2018 - 2030 (USD Million)
• 5.5. Supportive Care
  • 5.5.1. Supportive Care Market, 2018 - 2030 (USD Million)
• 5.6. Lipid Modifying Agents
  • 5.6.1. Lipid Modifying Agents Market, 2018 - 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Lysosomal Acid Lipase Deficiency Treatment Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Norway
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Norway Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Denmark
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Denmark Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Sweden
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Sweden Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. South Korea Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Australia Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Alexion Pharmaceuticals, Inc. (AstraZeneca)
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Amgen Inc.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. BioCrick BioTech
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Lupin
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Merck KGaA
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Pfizer Inc.
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Regeneron Pharmaceuticals Inc.
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Teva Pharmaceutical Industries Ltd
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives